Holen Sie sich die Stockscreener-App
1.25
3.85%
-0.05
Handel nachbörslich:
1.28
0.03
+2.40%
Schlusskurs vom Vortag:
$1.30
Offen:
$1.3
24-Stunden-Volumen:
276.58K
Relative Volume:
1.70
Marktkapitalisierung:
$21.75M
Einnahmen:
$486.00K
Nettoeinkommen (Verlust:
$-28.43M
KGV:
-0.4434
EPS:
-2.8189
Netto-Cashflow:
$-26.75M
1W Leistung:
-12.59%
1M Leistung:
-19.61%
6M Leistung:
-58.33%
1J Leistung:
-53.18%
1-Tages-Spanne:
$1.18
$1.30
1-Wochen-Bereich:
$1.18
$1.43
52-Wochen-Spanne:
$1.18
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Firmenname
Vyne Therapeutics Inc
Sektor
Branche
Telefon
800-775-7936
Adresse
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Vergleichen Sie VYNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
1.25 | 21.75M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Eingeleitet | BTIG Research | Buy |
| 2021-12-06 | Fortgesetzt | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Aktie (VYNE) Neueste Nachrichten
VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Vyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
VYNE Therapeutics Inc Q1 2025 Earnings: EPS of -$0.20 Beats Estimate, Revenue of $0.2 Million Exceeds Forecast - GuruFocus
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - The Manila Times
Renaissance Technologies LLC Decreases Stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Therapeutics Inc (VYNE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Closing Strong: VYNE Therapeutics Inc (VYNE) Ends at 1.43, Down -23.94 from Last Close - DWinneX
Market Watch: Renovaro Inc (RENB)’s Noteworthy Gain, Closing at 0.37 - DWinneX
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
HC Wainwright Cuts VYNE Therapeutics (NASDAQ:VYNE) Price Target to $4.50 - Defense World
FDA places clinical hold on VYNE’s psoriasis drug study - Investing.com
VYNE stock touches 52-week low at $1.38 amid market challenges - Investing.com
After A -27.64% Drop In Share Price, Is VYNE Therapeutics Inc (NASDAQ:VYNE) A Better Trade Than Others? - Marketing Sentinel
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - AOL.com
VYNE Therapeutics Inc (VYNE) Stock: A Year of Highs and Lows in the Market - investchronicle.com
VYNE stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
FDA places clinical hold on VYNE’s psoriasis drug study By Investing.com - Investing.com South Africa
VYNE Therapeutics Provides Update on VYN202 Program | VYNE Stock News - GuruFocus
VYNE’s earnings forecast for the current quarter - uspostnews.com
VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down. - Nasdaq
FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis - Dermatology Times
VYNE Therapeutics (VYNE) Target Price Cut Following FDA Clinical - GuruFocus
VYNE Therapeutics (VYNE) Faces FDA Clinical Hold on Psoriasis Dr - GuruFocus
With 36.89% Distance From Low, Could Vs Media Holdings Ltd (NASDAQ:VSME) Post Further Gains? - Marketing Sentinel
Pre-market Movers: OMEX, SES, VYNE, OLB, LEXX… - RTTNews
VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell - marketscreener.com
VYNE Therapeutics Provides Update on VYN202 Program - The Manila Times
VYNE Therapeutics Psoriasis Drug Trial Suspended: FDA Flags Critical Safety Issues in Animal Studies - Stock Titan
VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.1% – Here’s What Happened - Defense World
Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Yahoo Finance
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN
Invesco Canada announces cash distributions for its ETFs - The Globe and Mail
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World
VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com
VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz
VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World
Finanzdaten der Vyne Therapeutics Inc-Aktie (VYNE)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):